Kymera Therapeutics (KYMR) Accumulated Expenses (2019 - 2025)
Historic Accumulated Expenses for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $28.6 million.
- Kymera Therapeutics' Accumulated Expenses rose 794.95% to $28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.6 million, marking a year-over-year increase of 794.95%. This contributed to the annual value of $34.9 million for FY2024, which is 296.18% up from last year.
- As of Q3 2025, Kymera Therapeutics' Accumulated Expenses stood at $28.6 million, which was up 794.95% from $28.0 million recorded in Q2 2025.
- In the past 5 years, Kymera Therapeutics' Accumulated Expenses registered a high of $34.9 million during Q4 2024, and its lowest value of $10.6 million during Q1 2021.
- For the 5-year period, Kymera Therapeutics' Accumulated Expenses averaged around $23.4 million, with its median value being $23.1 million (2025).
- Per our database at Business Quant, Kymera Therapeutics' Accumulated Expenses soared by 14408.18% in 2021 and then crashed by 1353.91% in 2024.
- Over the past 5 years, Kymera Therapeutics' Accumulated Expenses (Quarter) stood at $23.0 million in 2021, then increased by 19.72% to $27.5 million in 2022, then increased by 23.13% to $33.9 million in 2023, then grew by 2.96% to $34.9 million in 2024, then decreased by 17.86% to $28.6 million in 2025.
- Its Accumulated Expenses stands at $28.6 million for Q3 2025, versus $28.0 million for Q2 2025 and $23.1 million for Q1 2025.